The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib

BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some p...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Dong Il, Kim, Sun Young, Kim, Ju Ock, Jung, Sung Soo, Park, Hee Sun, Moon, Jae Young, Chung, Chae Uk, Kim, Song Soo, Seo, Jae Hee, Lee, Jeong Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620323/
https://www.ncbi.nlm.nih.gov/pubmed/26508917
http://dx.doi.org/10.4046/trd.2015.78.4.315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620323/
https://www.ncbi.nlm.nih.gov/pubmed/26508917
http://dx.doi.org/10.4046/trd.2015.78.4.315

Ejemplares similares